Avaxia Biologics, Inc. Awarded Patent With Broad Coverage Over Oral Anti-TNF Antibodies For Inflammatory Bowel Disease

LEXINGTON, Mass.--(BUSINESS WIRE)--Avaxia Biologics, Inc., a clinical-stage biopharmaceutical company developing gut-targeted therapeutics, announced today that the company was awarded U.S. Patent No. 8,647,626, entitled “Compositions Comprising TNF-specific Antibodies for Oral Delivery.”

Help employers find you! Check out all the jobs and post your resume.